|
1.
|
Gaga M, Powell CA, Schraufnagel DE,
Schönfeld N, Rabe K, Hill NS and Sculier JP: ATS/ERS Task Force on
the Role of the Pulmonologist in the Management of Lung Cancer: An
official American Thoracic Society/European Respiratory Society
statement: The role of the pulmonologist in the diagnosis and
management of lung cancer. Am J Respir Crit Care Med. 188:503–507.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Zhi X, Wu Y, Ma S, Wang T, Wang C, Wang J,
Shi Y, Lu Y, Liu L, Liu D, et al: Chinese guidelines on the
diagnosis and treatment of primary lung cancer (2011 version).
Zhongguo Fei Ai Za Zhi. 15:677–688. 2012.(In Chinese). PubMed/NCBI
|
|
3.
|
Li HR and Sun F: Erlotinib serious adverse
reactions and preventive measures. Chin J Pharmacoepidemiol.
19:232–233. 2010.(In Chinese).
|
|
4.
|
Orphanos GS, Ioannidis GN and Ardavanis
AG: Cardiotoxicity induced by tyrosine kinase inhibitors. Acta
Oncol. 48:964–970. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Chu TF, Rupnick MA, Kerkela R, Dallabrida
SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai
J, et al: Cardiotoxicity associated with tyrosine kinase inhibitor
sunitinib. Lancet. 370:2011–2019. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Reck M, Mok T, Wolf J, Heigener D and Wu
YL: Reviewing the safety of erlotinib in non-small cell lung
cancer. Expert Opin Drug Saf. 10:147–157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Merimsky O, Cheng CK, Au JS, von Pawel J
and Reck M: Efficacy and safety of first-line erlotinib in elderly
patients with advanced non-small cell lung cancer. Oncol Rep.
28:721–727. 2012.PubMed/NCBI
|
|
8.
|
Reck M, van Zandwijk N, Gridelli C, Baliko
Z, Rischin D, Allan S, Krzakowski M and Heigener D: Erlotinib in
advanced non-small cell lung cancer: Efficacy and safety findings
of the global phase IV Tarceva Lung Cancer Survival Treatment
study. J Thorac Oncol. 5:1616–1622. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Wu YL, Kim JH, Park K, Zaatar A,
Klingelschmitt G and Ng C: Efficacy and safety of maintenance
erlotinib in Asian patients with advanced non-small-cell lung
cancer: A subanalysis of the phase III, randomized SATURN study.
Lung cancer. 77:339–345. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Doherty KR, Wappel RL, Talbert DR, Trusk
PB, Moran DM, Kramer JW, Brown AM, Shell SA and Bacus S:
Multi-parameter in vitro toxicity testing of crizotinib, sunitinib,
erlotinib and nilotinib in human cardiomyocytes. Toxicol Appl
Pharmacol. 272:245–255. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Wu X, Gao G, Ren S and Zhou C: Four cases
of interstitial lung disease induced by erlotinib and a review of
the literatures. Zhongguo Fei Ai Za Zhi. 15:494–498. 2012.(In
Chinese). PubMed/NCBI
|
